However, the prognosis for CML improved considerably since the use of tyrosine kinase inhibitors (TKIs), most notably imatinib in the early 2000s, which inhibit the BCR-ABL1 fusion protein by blocking its kinase domain [120]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.